BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
See today's BioWorld
Home
» Invitrogen Paying $47M In Cash For Software Provider InforMax
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Invitrogen Paying $47M In Cash For Software Provider InforMax
Oct. 16, 2002
By
Randy Osborne
No Comments
Invitrogen Corp. aims to create a "desktop to lab bench" tool set with its buyout of InforMax Inc. in an all-cash transaction valued at $1.36 per share, or about $42 million for the fully diluted equity. (BioWorld Today)
BioWorld